Further understanding of the molecular biology and pathogenesis of hepatocellular carcinoma (HCC) is crucial for future therapeutic development. SMAD4, recognized as an important tumor suppressor, is a central mediator of transforming growth factor beta (TGFB) and bone morphogenetic protein (BMP) signaling. This study investigated the role of SMAD4 in HCC. Nuclear localization of SMAD4 was observed in a cohort of 140 HCC patients using tissue microarray. HCC cell lines were used for functional assay in vitro and in immune-deficient mice. Nuclear SMAD4 levels were significantly increased in patient HCC tumors as compared with adjacent tissues. Knockdown of SMAD4 significantly reduced the efficiency of colony formation and migratory capacity of HCC cells in vitro and was incompatible with HCC tumor initiation and growth in mice. Knockdown of SMAD4 partially conferred resistance to the anti-growth effects of BMP ligand in HCC cells. Importantly, simultaneous elevation of SMAD4 and phosphorylated SMAD2/3 is significantly associated with poor patient outcome after surgery. Although high levels of SMAD4 can also mediate an antitumor function by coupling with phosphorylated SMAD1/5/8, this signaling, however, is absent in majority of our HCC patients. In conclusion, this study revealed a highly non-canonical tumor-promoting function of SMAD4 in HCC. The drastic elevation of nuclear SMAD4 in sub-population of HCC tumors highlights its potential as an outcome predictor for patient stratification and a target for personalized therapeutic development.
INTRODUCTION SMAD proteins are recognized as central mediators of transforming growth factor beta (TGFB) and/or bone morphogenetic protein (BMP) signaling pathways, which regulate a plethora of physiological processes including cell growth and differentiation. 1 Accordingly, deregulation of TGFB/BMP pathways almost invariably leads to developmental defects and/or diseases, in particular cancer. 2 These two pathways signal through the family of SMAD proteins to exert their effects. In mammals, there are eight SMADs that are subdivided into three distinct classes: receptor-regulated SMADs (R-SMADs) comprising SMAD2 and SMAD3 (transduce TGFB signaling) and SMAD1, SMAD5 and SMAD8 (transduce BMP signaling); a common SMAD called SMAD4; and two inhibitory SMADs, namely, SMAD6 and SMAD7. 3 SMAD proteins are highly conserved within their family and across species, with SMAD4 representing a somewhat divergent subtype, which still retains about 40% identity with other family members. 4 SMAD4 binds to R-SMADs and forms heteromeric complexes and facilitating the translocation of these heteromeric complexes into the nucleus. In the nucleus, the heteromeric complex binds to promoters and interacts with transcriptional activators 2, 5 and the presence of nuclear SMAD4 protein has profound consequences for gene expression.
Originally identified as a candidate tumor-suppressor gene at 18q21.1 decades ago, 6 the tumor-suppressive function of SMAD4 has now almost achieved dogmatic status and loss of its activity has been implicated in the initiation and progression of a multitude of cancer types. 2, [7] [8] [9] [10] Loss or inactivation of both normal gene copies is associated with carcinoma in several organ systems, including approximately 55% of pancreatic adenocarcinomas, 6 15-55% of extrahepatic cholangiocarcinomas 11 and a smaller percentage of gastrointestinal and other carcinomas. 12, 13 Strikingly, loss of SMAD4 expression in hepatocellular carcinoma (HCC) has not been observed, prompting investigations into role and importance of this tumor suppressor in this disease. Hence, we endeavored to establish the role of SMAD4 in HCC, which we uncovered a non-conventional function of SMAD4 in HCC as a tumor promoter. in patient HCC tissues. We have searched the database of the cBioPortal for Cancer Genomics. We identified three cohorts of total 457 HCC patients with genomics data of SMAD4 gene (Figure 1a ). There are only two patients identified to harbor mutations (R87W; A462T), suggesting that SMAD4 gene mutation in HCC is rather rare, in contrast to pancreatic or colorectal cancers (up to 20-30%) ( Figure 1a ). In addition, one HCC patient was found to have SMAD4 gene amplification and another one has SMAD4 deletion ( Figure 1a ).
We further searched the Oncomine microarray database to analyze mRNA expression of SMAD4 in patient HCC. In total, we have identified five cohorts of 424 HCC tissue samples compared with 344 liver tissues. SMAD4 mRNA was upregulated in all the cohorts. By polling all the cohorts, there is a significant increase of SMAD4 mRNA expression in the HCC tumor compared with liver tissue (P o0.05) ( Figure 1b ). These data indicate that genomic alteration is rare but elevation of mRNA expression is common in patient HCC tumor.
Drastic elevation of nuclear SMAD4 expression in the tumors of sub-population of HCC patients
The paucity of data surrounding the functionality of SMAD4 in HCC prompted us to analyze SMAD4 expression and activation in a panel of resected HCC from 140 individual patients and compare the results with adjacent non-transformed tissue. In these patients, nuclear SMAD4 protein ( Figure 2a ) was taken as measure of SMAD4 signaling activity, as it is generally assumed that this fraction of the SMAD4 pool represents the transcriptionally active form of the protein. The staining was scored by two independent investigators with a Kappa test of 0.773, suggesting that there was an excellent agreement in scoring between the two investigators. The levels of SMAD4 protein positivity range from low (score: 0-o 2), moderate (score: 2-o 3) to high (score: 3-4) both in the HCC tumors and their adjacent sites (Figures 2a and b ). Interestingly, nuclear SMAD4 levels were considerably higher in human HCC tissue as compared with normal adjacent liver tissue (n = 140, P o0.01) (Figures 2a and c) , which is consistent with the upregulation of mRNA expression in HCC ( Figure 1b ). Subsequent subgroup analysis according to the nuclear SMAD4 score in the tumor showed that there was no difference of SMAD4 levels between tumor and adjacent tissue in patients displaying low-to-moderate nuclear SMAD4 scores (n = 97, data not shown); whereas a drastic elevation was observed in tumor compared with adjacent tissue in the high SMAD4 expression group, (3.47 ± 0.45 vs 2.27 ± 0.92, mean ± s.e.m., n = 43, Po 0.001) ( Figure 2c ).
Analysis focusing on clinical behavior of the cancer ( Supplementary Table S1 ) revealed that high levels of nuclear SMAD4 were not significantly associated with tumor size (n = 98 analyzable patients), number of tumor lesions (n = 129 analyzable patients) and vascular invasion (n = 78 analyzable patients), but significantly associated with higher levels of alpha-fetoprotein preresection (n = 135 analyzable patients, P o 0.01). Serum alphafetoprotein has been suggested as an independent indicator for HCC prognosis and patients with high alpha-fetoprotein levels have been reported to have shorter survival. 14 In addition, SMAD4 is significantly associated with fibrosis (P o 0.01) (Supplementary Figure S1 ). Liver fibrosis is in turn strongly correlated with HCC development. 15 Furthermore, nuclear SMAD4 level was significantly higher in undifferentiated tumor than in well-differentiated tumor of HCC (2.53 ± 0.23 vs 1.94 ± 0.11, mean ± s.e.m., n = 127, Po 0.05) ( Figure 2d ). Importantly although, apparently high SMAD4 positivity in surgically resected HCC (n = 130 analyzable patients) tend to have higher risk of fast recurrence (hazard ratio (HR) = 1.420, 95% confidence interval (CI): 0.711-2.836 in the high-level group) and higher risk of poor survival (HR = 1.844, 95%CI: 0.894-3.803 in the high-level group) (Figures 2e and f). Kaplan-Meier analysis (n = 130 analyzable patients) also indicated a trend of shorter time to recurrence and lower cumulative survival in high SMAD4 level patients, although not statistically significant (Figures 2e and f). We interpreted that higher nuclear SMAD4 levels may be associated with more aggressive types of tumors in HCC patients.
Silencing of SMAD4 expression reduced colony formation in human hepatoma cell lines In order to obtain an insight into the mechanisms possibly mediating the negative relation between SMAD4 signaling and HCC clinical behavior, we used lentiviral RNA interference vectors expressing short hairpin RNA (sh-SMAD4) to stably knockdown SMAD4 expression in human HCC cell lines and subsequently characterized the cellular consequences thereof. Supplementary Figure S2 showed the efficacy of gene silencing using this strategy. A vector expressing short hairpin RNA targeting green fluorescent protein served as control (CTR). The success of this approach was confirmed by western blot and probing for SMAD4 protein (Figure 3a ), which showed almost absence of the protein in the knockdown cell lines, whereas the control cell lines remain SMAD4 proficient. Using immunofluorescent staining, it has confirmed the efficiency of SMAD4 knockdown in Huh7, Huh6 and PLC cell lines ( Figure 3b ).
Colony formation assay is a robust tool to evaluate the ability of a single cell to support proliferation. Using this assay, we observed a significant decrease in the numbers of formed colonies in Huh7 cells with SMAD4 knockdown compared with the mock cells (CTR vs sh-SMAD4: 270.8 ± 25.82 vs 144.8 ± 32.11 colonies per 1000 cells, mean ± s.d., n = 4, Po 0.05) ( Figure 3c ). Similar results were observed in Huh6 and PLC cells ( Figure 3c ). Thus, in contrast to most other cell types where SMAD4 expression is associated with reduced cancer cell growth, SMAD4 expression supports proliferation of HCC cells.
Knockdown of SMAD4 attenuated the ability of HCC cell migration
Cell migration is a fundamental function underlying cellular processes including invasion or metastasis of cancer cells. We thus investigated the role of SMAD4 in migration of HCC cells using a ring-barrier system ( Figure 4a ). Silencing of SMAD4 expression resulted in attenuated migratory capacity toward the cell-free area in Huh7 cells. In Huh7 cells with SMAD4 knockdown, quantification revealed a significant reduction in total migration (CTR vs sh-SMAD4: 174.1 ± 54.3 μm vs 128.7 ± 42.1 μm, mean ± s.d., n = 30, Po 0.01), effective migration (CTR vs sh-SMAD4: 109.1 ± 33.2 μm vs 55.4 ± 22.4 μm, mean ± s.d., n = 30, P o 0.001), migration efficiency (CTR vs sh-SMAD4: 63.60 ± 9.60% vs 43.95 ± 16.62% mean ± s.d., n = 30, P o0.0001) and migration velocity (CTR vs sh-SMAD4: 7.3 ± 2.3 vs 5.4 ± 1.8 μm/h, mean ± s.d., n = 30, P o 0.001) ( Figure 4b ). These results indicate that SMAD4 in HCC cells support migration and in conjunction with the colony formation data support the notion of a non-canonical pro-oncogenic function of SMAD4 in HCC.
Silencing of SMAD4 limited hepatoma initiation and growth in mice
To finally ensure the tumor-promoting effects of SMAD4, we evaluated the impact of SMAD4 loss on tumor initiation and growth in nude mice. One million CTR and SMAD4 knockdown cells were subcutaneously injected into the left or right side of the mice, respectively. As shown in Figure 5 , impressively, knockdown of SMAD4 in Huh7 cells resulted in complete abolishment of tumor formation, whereas 7 out of 10 mice in the CTR group formed tumor (weight: 0.59 ± 0.15 g, mean ± s.e.m., n = 7). Collectively, this result is in line with the outcomes of our in vitro Figure 1 . SMAD4 gene mutation is rare but upregulation of its mRNA expression is common in patient HCC. (a) In the database of the cBioPortal for Cancer Genomics (http://www.cbioportal.org/public-portal/), three cohorts of total 457 HCC patients with genomics data of SMAD4 gene were identified. There are only two HCC patients harboring mutations (R87W; A462T). In addition, one HCC patient has SMAD4 gene amplification and another one has SMAD4 deletion. Green arrow indicated the cohort identified SMAD4 mutation (2 of 231 HCC patients); red arrow indicated the cohort identified SMAD4 copy number variation (2 of 199 patients); and dark arrow indicated the cohort withour genomic alteration identified (27 patients). (b) The Oncomine microarray database (https://www.oncomine.org) was searched to analyze mRNA expression of SMAD4 in patient HCC. In total, five cohorts of 424 HCC tissue samples compared with 344 liver tissues were identified. SMAD4 mRNA was upregulated in all the cohorts. There is a statistically significant increase of SMAD4 mRNA expression in the HCC tumor compared with liver tissue by polling all the cohorts. T-test was used for individual cohort. Meta-analysis of the five cohorts indicated its P-value for the median-ranked analysis. *P o0.05, **Po 0.01. experimentation and the observation that high SMAD4 expression in human HCC tissue is associated with worse prognoses firmly demonstrates that SMAD4 exerts a tumor-promoting role in HCC.
Simultaneous elevation of SMAD4 and phosphorylated SMAD2/3 is significantly associated with poor patient outcome Upon binding of the cognate ligands to the TGFB receptor, phosphorylated SMAD2/3 (p-SMAD2/3) binds to SMAD4 to form heteromeric complex, translocate to the nucleus and activate TGFB signaling. 16 The signaling receptors phosphorylate R-SMAD proteins at the carboxy-terminal (C-terminal) and the linker region. 17 Recent studies uncover a role for agonist-induced phosphorylation of the R-SMAD linker region 18 that may modulate downstream cellular responses to the TGFB family of ligands. We thus performed immunohistochemistry staining of p-SMAD2/3 both at the C-terminal phosphorylation (p-SMAD2/3C, Ser423/425) and the linker phosphorylation region (p-SMAD2/3L, Thr220/179) in the tissue microarray (TMA) that was used for SMAD4 staining (Figures 6a and 7a ). The patient groups (low, moderate or high) is categorized according to expression levels in the tumors. Although no significant difference overall (n = 140), p-SMAD2/3C levels were significantly lower in HCC tissue as compared with normal adjacent liver tissue in patients with low-to-moderate scores (n = 86, P o0.001, data not shown); whereas it is significantly higher in the tumor of in patients with high scores (n = 54, P o 0.001) ( Figure 6b ). Moreover, overall p-SMAD2/3L expression was significantly higher in the HCC tumor than in the adjacent area (P o 0.001) ( Figure 7b ). High p-SMAD2/3C expression in tumor is significantly associated with high recurrence rate (n = 47, P o0.05) and patient death rate (n = 44, P o0.05) (Supplementary Table 2 ). Cox regression and Kaplan-Meier analysis (n = 140) also revealed a tendency of shorter time to recurrence and a trend to less cumulative survival in patients with high levels of p-SMAD2/3-C/L in the tumor HCC ( Figures 6c and d  and 7c ).
As a phosphorylated protein, moderate levels of p-SMAD2/3-C/L would be expected to be already sufficient to trigger the downstream signaling transduction in the presence of SMAD4. A sub-population of HCC patients have a simultaneous elevation of SMAD4 and p-SMAD2/3C (n = 22) and p-SMAD2/3L (n = 34), which represents as a hallmark for the activation of the downstream signaling of TGFB (Supplementary Figure S3 and S4; Figures 6f and 7c ). Cox regression and Kaplan-Meier analysis also confirmed that these patients are significantly faster to disease recurrence and worse survival (P o0.05) (Figures 6f  and 7c ).
Nuclear p-SMAD3L (Ser213) binds to SMAD-binding element in the promoter with high affinity and specificity 19 and transmits fibrogenic/carcinogenic (fibro-carcinogenic) signaling. 20 Both pSMAD3C(Ser425) and p-SMAD3L(Ser213) form heterocomplexes with SMAD4, and move to nucleus. 21 Chronic inflammation and hepatitis viral additively shift hepatocytic SMAD3 signaling from tumor-suppressive pSMAD3C to fibrocarcinogenic p-SMAD3L. 22, 23 Therefore, we also investigated the expression of this particular form in our cohort. p-SMAD3L levels were significantly higher in HCC tissue as compared with normal adjacent liver tissue. (P o 0.001, Figure 7e ). Cox regression analysis and Kaplan-Meier analysis (n = 131) indicated that patients with high level of p-SMAD3L have worse survival (HR = 1.155, 95% CI: 1.117-5.371 in the high-level group) and these features were also seen in co-expression of SMAD4 and p-SMAD3L (Figure 7f ). Taken together ( Figures 6 and 7 ; Supplementary Tables S2-S7 ), these results indicate that SMAD4 together with p-SMAD2/3, both C-terminal (C) and linker phosphorylation (L), with Ser or Thr residues, exert a tumorpromoting function in HCC patients.
An antitumor signaling mediated by phosphorylated SMAD1/5/8 and SMAD4 is inactivated in majority of HCC patients Upon binding of BMP ligands, phosphorylated SMAD1/5/8 (p-SMAD1/5/8) binds to SMAD4 to form heteromeric complex, translocate to the nucleus and activate BMP signaling. 16 Although Tumor-promoting role of SMAD4 in HCC the exact role of BMP signaling in cancer is highly context dependent, a recent study demonstrated that BMP4, a BMP ligand, inhibited the tumorigenic capacity of HCC cells. 24 We further examined the effects of BMP4 on HCC cells. In Huh7 cells, BMP4 significantly reduces colony formation ability of Huh7 cells and knockdown of SMAD4 attenuated the effects of BMP4. The efficiency of colony formation was reduced by BMP4 treatment in CTR cells by 47.02 ± 6.5% but only by 25.3 ± 6.4% in SMAD4 knockdown Huh7 cells (mean ± s.d., n = 4, P o 0.01) (Figure 8a) . Consistently, adding BMP inhibitor Noggin appears to increase the efficiency of colony formation in CTR cells (124.5 ± 19.1%, mean ± s.d., n = 4) but has much less effect (109.6 ± 9.5%, mean ± s.d., n = 4) in SMAD4 knockdown Huh7 cells (Figure 8b) . Thus, BMP4 significantly reduced the colony formation ability of hepatoma cells, which was consistent with previous reports in other cancer, [25] [26] [27] and knockdown of SMAD4 attenuated the effects of BMP4. Western blot analysis showed the effects of BMP4 and Noggin on the protein levels of SMAD4, p-SMAD2/3 and p-SMAD1/5/8. This was in broad agreement with the efficacy of the experimental strategy but also suggested the existence of SMAD4-dependent feedback loops on BMP signaling elements (Figures 8c and d) . Our results confirm that activation of BMP signaling, which involves both SMAD4 and p-SMAD1/5/8, exerts anti-HCC effects.
Next, we further explored the role of this pathway in our HCC cohort. Immunohistochemistry staining of p-SMAD1/5/8 was performed in the TMA (n = 140), and was scored and categorized as described before (Figures 9a and b ). Although p-SMAD1/5/8 is significantly higher in the tumor tissue compared with adjacent liver tissue (Figure 9c ), only a small subset of patients have high levels of p-SMAD1/5/8 in the tumor (17 out of 140, see Supplementary Table S8 ). No significant relation was observed regarding to the size (n = 98) and the number of tumor foci (n = 129) ( Supplementary Table S8 ). Interestingly, a Bonferronicorrected clinical parameter analysis revealed a negative correlation between tumor p-SMAD1/5/8 level and age ( Supplementary  Table S8 ). Patients with high levels of p-SMAD1/5/8 appear to have lower risk of fast recurrence (HR = 0.542, 95% CI: 0.191-1.538 in the high-level group) and lower risk to poor survival (HR = 0.596, 95% CI: 0.210-1.697 in the high-level group) (Figure 9d ). Kaplan-Meier analysis also revealed a trend of longer time to recurrence and higher cumulative survival in these patients (Figure 9d) .
As a phosphorylated protein, p-SMAD1/5/8 could sensitively control the downstream signaling transduction. As the antitumor function of this signaling requires both SMAD4 and p-SMAD1/5/8, we further categorized the expression levels of both proteins in the same patients. As shown in Figure 9e , there are only eight patients having simultaneously sufficient levels of both SMAD4 and p-SMAD1/5/8 (n = 2 high; n = 6 moderate levels). These results suggest that SMAD4 and p-SMAD1/5/8-mediated antitumor signaling is inactivated in majority of our HCC patients.
DISCUSSION
In this study, we reported a drastic elevation of nuclear SMAD4 localization in tumors of subset of HCC patients. High expression of SMAD4 was further demonstrated to be functionally important for hepatoma formation and progression. Importantly, simultaneous elevation of SMAD4 and p-SMAD2/3 in subpopulation of HCC patients significantly associated with poor outcome after surgery. Although SMAD4 coupled with p-SMAD1-/5/8 can also mediate an antitumor effect, this signaling, however, is silent in majority of our HCC patients. Thus, we conclude that high nuclear SMAD4 expression has been screwed toward a tumor-promoting signaling in HCC (Supplementary Figure S5 ). This is unexpected in view of the dogma that SMAD4 is a potent tumor suppressor.
SMAD4 was initially described in pancreatic cancer, named DPC4 (deleted in pancreatic carcinoma, locus 4), and appears critical in pancreatic cancer progression. 28, 29 SMAD4 loss occurs in 40-50% of colon cancers, 30 which is associated with metastasis, advanced disease and reduced survival. Similarly, its loss in cholangiocarcinoma 31 or prostate cancer 8 is also related to more progressive disease. The tumor-suppressor function of SMAD4 is often closely linked to its capacity to mediate TGFB and BMP signals. However, we question whether activation or silencing of TGFB/BMP downstream components, including SMADs, is always ligand dependent in cancer? As in xenografts of human hepatoma cell lines in mice, which are thus unlikely to encounter their (human) ligands, we observed that high expression of SMAD4 is even required for tumor formation and growth. In contrast to our observation, a previous study has reported a lower protein level of SMAD4 in HCC tissue compared with adjacent liver tissue in an Asian cohort. 32 A possible explanation could be that the etiologies of HCC may influence the expression of SMAD4. In Asia, viral hepatitis is the main cause of HCC; whereas only o 30% of patients in our European cohort have viral hepatitis history, although high expression of SMAD4 was also reported in another Asian HCC cohort. 33 In addition, technical differences, including the source of antibody and the protocol of immunohistochemical staining, may also result in discrepancy. In this study, we have used a robust staining protocol for SMAD4 (see Materials and methods section) that was optimized and established in our previous studies. 34, 35 The essential role of TGFB/BMP signaling in cancer is certainly well documented, whereas its exact functions are also context dependent. 36 TGFB1 was also well recognized for its dual role in carcinogenesis. 37 It acts as a tumor suppressor in early stages of hepatocarcinogenesis by inducing apoptosis 38 and at a later stage, however, liver tumor cells often become resistant to its proapoptotic effect, and produce large amounts of TGFB themselves. 39 This was in line with our result that the different levels of phosphorylated R-SMADs is associated with distinct patient outcome. We speculate that dysregulation of key R-SMADs may lead to the opposite effect of the canonical TGFB and BMP signaling. In our HCC cohort, a sub-population of HCC patients have a simultaneous elevation of SMAD4 and p-SMAD2/3C (n = 22) or p-SMAD2/3L (n = 34), indicating the activation of TGFB downstream signaling. Both high expression of the C-terminal (C) and linker phosphorylation (L) region of p-SMAD2/3 are associated with worse outcome after surgical resection in our HCC cohort, which is in line with previous report in colorectal cancer, 40 confirming a tumor-promoting function of TGFB signaling in these HCC patients.
Several distinct BMP ligands were reported to act together to promote the migratory and invasive potential of cancer cells, 41 including in HCC. 42, 43 In contrast, a recent study demonstrated that BMP4 induced differentiation of HCC cancer stem cells and inhibited their tumorigenic capacity. 24 Our in vitro study indicated activating BMP signaling by adding BMP4 ligand in HCC was able to effectively suppress colony formation of HCC cells, which was consistent with previous reports in other cancer. [25] [26] [27] However, silencing of SMAD4 gene attenuated this effect, confirming that these anti-oncogenic actions require basal levels of SMAD4. Despite an antitumor effects of BMP pathway, this signaling, however, is silent in majority of our HCC patients, by losing the key components, either SMAD4 or p-SMAD1/5/8, or both of them. The obvious implication of this observation is that HCC cells should prove exquisitely sensitive to stimulation with BMP ligands mediating such signaling. In conjunction with the recent Food and Drug Administration approval of BMP2 and BMP7 as treatment for certain bone pathologies. 44 However, we have to be cautious that there are also studies reporting pro-oncogenic roles of BMP ligands in particular settings. For instance, BMP7 and BMP9 have been shown to have tumor-promoting functions in some experimental cancer (including HCC) models. 42, 45, 46 Nevertheless, our results call for further study exploiting this Achilles' heel of HCC.
In summary, this study reports a significant elevation of nuclear SMAD4 localization in patient HCC tumors. High nuclear SMAD4 has been screwed toward tumor-promoting effects because of simultaneous elevation of p-SMAD2/3 in subset of patients. SMAD4 can also mediate an antitumor signaling by coupling p-SMAD1/5/8; this complex, however, is absent in majority of patients because of lack of either SMAD4 or p-SMAD1/5/8, or both of them. These results have certainly shed new light on the molecular biology of HCC and more importantly SMAD-based molecules may have potential as outcome predictors for patient stratification.
Tumor-promoting role of SMAD4 in HCC
MATERIALS AND METHODS

Tissue microarray
To make TMA, paraffin-embedded HCC patient tissues (n = 140, between 2004 and 2013) were collected from the Pathology Department of Erasmus Medical Centre (Erasmus MC) Rotterdam. The use of patient materials was approved by the medical ethical committee of Erasmus MC (Medisch Ethische Toetsings Commissie Erasmus MC). 47, 48 Bioinformatics analysis of genomics and mRNA assay data sets To analyze the prevalence of genomic alterations of SMAD4 gene in patient HCC tissues, the database of the cBioPortal for Cancer Genomics (http:// www.cbioportal.org/public-portal/) was searched. Both copy number variation and gene mutation data were analyzed across cancer types with focusing on HCC.
To analyze mRNA expression of SMAD4 in HCC, the Oncomine microarray database (https://www.oncomine.org) was searched. SMAD4 mRNA expression was analyzed in identified cohorts by comparing expression levels in HCC tumors with liver tissues.
Immunohistochemistry
Paraffin-embedded liver tumor tissue in TMA slides were deparaffinized in xylene, rehydrated in graded alcohols. For antigen retrieval, slides were boiled in Tris/EDTA pH 9.0 for 30 min (for SMAD4 antibody) and 10 min for other antibodies; 3% H 2 O 2 was used to block endogenous peroxidase for 10 min at room temperature. The slides were incubated in 5% milk blocking solution followed by overnight incubation in mouse SMAD4 antibody (1:100 dilution, Santa Cruz Biotechnology, Inc., Huissen, The Netherlands), goat p-SMAD2/3C (Ser423/425) antibody (1:250 dilution, Santa Cruz Biotechnology, Inc.), mouse p-SMAD2/3L (Thr220/179) (1:250 dilution, Takara Bio, Shiga, Japan), mouse p-SMAD3L (Ser213) (1:250 dilution, Takara Bio), rabbit p-SMAD1/5/8 (1:500 dilution, Cell Signaling, Leiden, The Netherlands) and p-Histone H3 (1:1000 dilution, Merck Millipore, Amsterdam, The Netherlands), and then counterstained with hematoxylin. The SMAD4 scoring was based on the nuclear staining and the p-SMAD2/3 and p-SMAD1/5/8 scoring were based on cytoplasm and/or nuclear staining. The following scores were applied: score 0 for 0-10% positive staining, score 1 for 10-30% positive staining, score 2 for 30-70% positive staining, score 3 for 470% positive staining and 
Lentiviral short hairpin RNA vectors
Lentiviral backbone vectors for SMAD4 knockdown and non-targeting control were obtained from the Erasmus Center for Biomics (the Sigma-Aldrich TRC library, Zwijndrecht, The Netherlands). A vectors expressing short hairpin RNA targeting green fluorescent protein (not expressed in HCC cell lines) served as control (CTR). Lentiviral viral particles were generated as described previously. 49 Cell culture and reagents Human hepatoma cell lines (Huh7, Huh6 and PLC) were cultured in Dulbecco's modified Eagle's medium (Lonza, Breda, The Netherlands) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 1% penicillin/streptomycin (Gibco, Bleiswijk, The Netherlands). SMAD4 knockdown cells and control cells were generated by inoculation of lentiviral Figure 9 . The antitumor signaling mediated by p-SMAD1/5/8 and SMAD is inactivated in most of the HCC patients. (a) The levels of p-SMAD1/5/8 protein positivity range from low (score: 0-o2), moderate (score: 2-o 3) to high (score: 3-4) both in the HCC tumors and their adjacent sites. Scale bar, 100 pixels. (b) Different to SMAD4 or p-SMAD2/3, there were less patients with high p-SMAD1/5/8 score both in tumor and adjacent sites. (c) Overall p-SMAD1/5/8 expression was significantly higher in HCC tissue compared with adjacent liver tissue. The p-SMAD1/5/8 levels were also significantly higher in HCC tissue compared with adjacent tissue in the high-grade (n = 17) group. Error bars represents mean ± s.e.m., paired t-test, **P o0.01, ***Po 0.001. (d) From Cox regression analysis (n = 130), patients with high level of p-SMAD15/8 tend to have less risk of fast recurrence (HR = 0.542) and less risk to poor survival (HR = 0.596). Kaplan-Meier analysis (n = 130) showed similar trends. (e) However, there are only eight patients who have simultaneously sufficient levels of both SMAD4 and p-SMAD1/5/8 (n = 2 high; n = 6 moderate levels), suggesting that this signaling is inactivated in most of the HCC patients.
vectors and subsequently selected and maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 1% penicillin/streptomycin and 2 μg/ml puromycin (Sigma-Aldrich). Recombinant human BMP4 protein (100 μg/ml, Merck Millipore) and recombinant human Noggin (50 μg/ml, R&D System, Oxon, UK) were used to treat cells, respectively.
Colony forming assay
Colony formation was performed in Huh7 cells as described previously. 48 After trypsinizing, 1000 cells were added to each well of a six-well plate and were cultured in Dulbecco's modified Eagle's medium as previously described. The colonies formed are counterstained with hematoxylin and eosin after 2 weeks.
Western blotting
Subconfluent cells were lysed in Laemmli sample buffer containing 0.1 M dithiothreitol and incubated for 5 min at 96°C. Immunoblotting was performed using fluorescent Odyssey immunoblotting (LI-COR Biosciences, Lincoln, NE, USA). Antibodies used were mouse SMAD4 antibody (1:500 dilution, Santa Cruz Biotechnology, Inc.), goat p-SMAD2/3 antibody (1:500 dilution, Santa Cruz Biotechnology, Inc.) and rabbit p-SMAD1/5/8 (1:500 dilution, Cell Signaling). Quantification was performed using Odyssey LI-COR software.
Ring-barrier migration assay
Ring-barrier-based migration assays were performed as previously described. 50, 51 Huh7 and its sh-SMAD4 cells, 3 × 10 5 cells were seeded in the ring in Dulbecco's modified Eagle's medium+10% fetal bovine serum +1% penicillin/streptomycin. After 24 h, the migration barrier was removed and the cells were washed twice followed by the addition of fresh medium. All cell tracking measurements were conducted using AxioVision 4.9.1 (Carl Zeiss Microscopy, LLC, Thornwood, NY, USA). P-values were calculated using the two-tailed Mann-Whitney test. Track diagram images were processed in Adobe Illustrator CS6 (Adobe Systems Inc., San Jose, CA, USA).
HCC xenograft tumor in nude mice
HCC xenograft tumor model in nude mice was established as previously described. 52 Ten mice for each cell line (Huh7), aged 6-8 weeks, were subcutaneously engrafted with 1 million control (CTR) and SMAD4 knockdown cells into the lower left or right flank, respectively. Tumor initiation in the mice was monitored. At the end of experiment, mice were killed and tumors were harvested and weighed. The use of animals was approved by the Animal Care and Ethics Committee at Hangzhou Normal University, Hangzhou, China.
Statistical analysis
Statistical analysis was performed by using Χ 2 test, nonparametric Mann-Whitney test, Cox regression analysis and Kaplan-Meier survival analysis in IBM SPSS Statistical (IBM Corporation, Armonk, NY, USA). T-test was also used using GraphPad InStat software (GraphPad Software Inc., San Diego, CA, USA). P-values o 0.05 were considered as statistically significant.
